Therapeutic potential of peroxisome proliferator-activated receptor gamma agonist rosiglitazone in cerebral vasospasm after a rat experimental subarachnoid hemorrhage model

Journal of the Neurological Sciences

Volumn 305, Issue 1-2, 2011, Pages 85-91

  Wu, Yi ^a   Tang, Ke ^a   Huang, Ren Qiang ^a   Zhuang, Zong ^a   Cheng, Hui Lin ^a   Yin, Hong Xia ^a   Shi, Ji Xin ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Inflammation; PPAR gamma; Rosiglitazone; Subarachnoid hemorrhage; TLR4; Vasospasm

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; MYELOPEROXIDASE; ROSIGLITAZONE; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASILAR ARTERY; BRAIN VASOSPASM; CONTROLLED STUDY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; WESTERN BLOTTING;

ANIMALS; DISEASE MODELS, ANIMAL; MALE; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; THIAZOLIDINEDIONES; TOLL-LIKE RECEPTOR 4; VASODILATOR AGENTS; VASOSPASM, INTRACRANIAL;

EID: 79955701023     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2011.03.006     Document Type: Article

References (50)

1. Keyrouz SG, Diringer MN. Clinical review: prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care 2007;11:220.
2. Dumont AS, Dumont RJ, Chow MM, Lin CL, Calisaneller T, Ley KF, et al. Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery 2003;53:123-33 Discussion 133-125.
3. Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schutt S, et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry 2001;70:534-7. (Pubitemid 32269696)
4. Gruber A, Rossler K, Graninger W, Donner A, Illievich MU, Czech T. Ventricular cerebrospinal fluid and serum concentrations of sTNFR-I, IL-1ra, and IL-6 after aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol 2000;12:297-306.
5. Lu H, Shi JX, Chen HL, Hang CH, Wang HD, Yin HX. Expression of monocyte chemoattractant protein-1 in the cerebral artery after experimental subarachnoid hemorrhage. Brain Res 2009;1262:73-80.
6. McGirt MJ, Lynch JR, Blessing R, Warner DS, Friedman AH, Laskowitz DT. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 2002;51:1128-34 Discussion 1134-1125.
7. Osuka K,Watanabe Y, Yamauchi K, Nakazawa A, Usuda N, Tokuda M, et al. Activation of the JAK-STAT signaling pathway in the rat basilar artery after subarachnoid hemorrhage. Brain Res 2006;1072:1-7. (Pubitemid 43255443)
8. Sasaki T, Kasuya H, Onda H, Sasahara A, Goto S, Hori T, et al. Role of p38 mitogenactivated protein kinase on cerebral vasospasm after subarachnoid hemorrhage. Stroke 2004;35:1466-70. (Pubitemid 38697477)
9. Yatsushige H, Yamaguchi M, Zhou C, Calvert JW, Zhang JH. Role of c-Jun N-terminal kinase in cerebral vasospasm after experimental subarachnoid hemorrhage. Stroke 2005;36:1538-43. (Pubitemid 40967526)
10. Zhou ML, Shi JX, Hang CH, Cheng HL, Qi XP, Mao L, et al. Potential contribution of nuclear factor-kappaB to cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. J Cereb Blood Flow Metab 2007;27:1583-92. (Pubitemid 47301442)
11. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801. (Pubitemid 43261452)
12. Curtiss LK, Tobias PS. The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis. Curr Drug Targets 2007;8:1230-8.
13. Coenen KR, Gruen ML, Lee-Young RS, Puglisi MJ, Wasserman DH, Hasty AH. Impact of macrophage toll-like receptor 4 deficiency on macrophage infiltration into adipose tissue and the artery wall in mice. Diabetologia 2009;52:318-28.
14. Dasu MR, Riosvelasco AC, Jialal I. Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 2009;202:76-83.
15. Balistreri CR, Colonna-Romano G, Lio D, Candore G, Caruso C. TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases. J Clin Immunol 2009;29:406-15.
16. Klein M, Obermaier B, Angele B, Pfister HW, Wagner H, Koedel U, et al. Innate immunity to pneumococcal infection of the central nervous system depends on toll-like receptor (TLR) 2 and TLR4. J Infect Dis 2008;198:1028-36.
17. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007;104:13,798-803.
18. Y. Wu, X.D. Zhao, Z. Zhuang, Y.J. Xue, H.L. Cheng, H.X. Yin, et al. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin- induced Toll-like receptor 4 expression in vascular smooth muscle cells. Brian Res 2010;1322:102-108.
19. Zhou ML, Wu W, Ding YS, Zhang FF, Hang CH, Wang HD, et al. Expression of Tolllike receptor 4 in the basilar artery after experimental subarachnoid hemorrhage in rabbits: a preliminary study. Brain Res 2007;1173:110-6. (Pubitemid 47445451)
20. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
21. Clark RB. The role of PPARs in inflammation and immunity. J Leukoc Biol 2002;71: 388-400.
22. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008;13:1813-26. (Pubitemid 351599735)
23. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, et al. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006;530:70-80. (Pubitemid 43037126)
24. Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Del Rio J, Frechilla D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 2009;379:406-10.
25. Huang W, Eum SY, Andras IE, Hennig B, Toborek M. PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J 2009;23: 1596-606.
26. McTigue DM, Tripathi R, Wei P, Lash AT. The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol 2007;205:396-406. (Pubitemid 46755761)
27. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and antioxidative mechanisms. Brain Res 2008;1244:164-72.
28. Pereira MP, Hurtado O, Cardenas A, Alonso-Escolano D, Bosca L, Vivancos J, et al. The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J Neuropathol Exp Neurol 2005;64:797-805. (Pubitemid 41285813)
29. Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptorgamma agonist rosiglitazone. J Neurochem 2006;97:435-48.
30. Makino N, Sugano M, Satoh S, Oyama J, Maeda T. Peroxisome proliferator-activated receptor-gamma ligands attenuate brain natriuretic peptide production and affect remodeling in cardiac fibroblasts in reoxygenation after hypoxia. Cell Biochem Biophys 2006;44:65-71. (Pubitemid 43099572)
31. Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, et al. PPAR-gamma-mediated neuroprotection in a chronicmouse model of Parkinson's disease. Eur J Neurosci 2009;29:954-63.
32. Xu J, Barger SW, Drew PD. The PPAR-gamma agonist 15-deoxy-delta- prostaglandin J(2) attenuates microglial production of IL-12 family cytokines: potential relevance to Alzheimer's disease. PPAR Res 2008;2008:349185.
33. Dasu MR, Park S, Devaraj S, Jialal I. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009;150:3457-64.
34. Eun CS, Han DS, Lee SH, Paik CH, Chung YW, Lee J, et al. Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway. Dig Dis Sci 2006;51:693-7.
35. Vatter H, Weidauer S, Konczalla J, Dettmann E, Zimmermann M, Raabe A, et al. Time course in the development of cerebral vasospasm after experimental subarachnoid hemorrhage: clinical and neuroradiological assessment of the rat double hemorrhage model. Neurosurgery 2006;58:1190-7 Discussion 1190-1197.
36. Seifert V, Stolke D, Reale E. Ultrastructural changes of the basilar artery following experimental subarachnoid haemorrhage. A morphological study on the pathogenesis of delayed cerebral vasospasm. Acta Neurochir Wien 1989;100:164-71.
37. Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2005:CD000277.
38. Komotar RJ, Zacharia BE, Valhora R, Mocco J, Connolly Jr ES. Advances in vasospasm treatment and prevention. J Neurol Sci 2007;261:134-42. (Pubitemid 47313506)
39. Pradilla G, Thai QA, Legnani FG, Clatterbuck RE, Gailloud P, Murphy KP, et al. Local delivery of ibuprofen via controlled-release polymers prevents angiographic vasospasm in a monkey model of subarachnoid hemorrhage. Neurosurgery 2005;57:184-90 Discussion 184-190.
40. Gu H, Tang C, Peng K, Sun H, Yang Y. Effects of chronicmild stress on the development of atherosclerosis and expression of toll-like receptor 4 signaling pathway in adolescent apolipoprotein E knockoutmice. J Biomed Biotechnol 2009;2009:613879.
41. Miller YI, Choi SH, Fang L, Harkewicz R. Toll-like receptor-4 and lipoprotein accumulation in macrophages. Trends Cardiovasc Med 2009;19:227-32.
42. Aoki T, Nishimura M, Ishibashi R, Kataoka H, Takagi Y, Hashimoto N. Toll-like receptor 4 expression during cerebral aneurysm formation. J Neurosurg 2010;113 (4):851-8.
43. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002;2:748-59. (Pubitemid 37328715)
44. Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S. PPARregulationof inflammatory signaling in CNS diseases. PPAR Res 2008;2008:658520.
45. Drew PD, Xu J, Racke MK. PPAR-gamma: therapeutic potential for multiple sclerosis. PPAR Res 2008;2008:627463.
46. Zhao X, Sun G, Zhang J, Strong R, SongW, Gonzales N, et al. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferatoractivated receptor gamma in microglia/macrophages. Ann Neurol 2007;61:352-62. (Pubitemid 46676735)
47. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma- mediated effects in the vasculature. Circ Res 2008;102:283-94. (Pubitemid 351271648)
48. Meredith D, Panchatcharam M, Miriyala S, Tsai YS, Morris AJ, Maeda N, et al. Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol 2009;29:465-71.
49. Ji Y, Liu J, Wang Z, Liu N, Gou W. PPARgamma agonist, rosiglitazone, regulates angiotensin II - induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest 2009;89:887-902.
50. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009;158:1007-20.